0845 GMT - A merger between GSK and AstraZeneca could be a possibility given incoming GSK CEO Luke Miels's strong background and history with Astra CEO Pascal Soriot, Baader Europe analyst Abhishek Raval writes. Miels has worked closely with Soriot over the past ten years and there is no major overlap between the two companies' offerings, Raval says. With Soriot due to turn 67 next year, Astra might not have problems being lead by its current CEO's mentor, Raval writes. GSK shares have climbed 23% since late September, which Raval says could be linked to Miels's background leading big pharma. "In a nutshell, GSK's share price rally may still have more steam left," Raval writes. GSK shares are down 0.3% and Astra is down 0.1%. (ian.walker@wsj.com)

(END) Dow Jones Newswires

December 30, 2025 03:45 ET (08:45 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.